Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country

Rhea-AI Summary

Emergent BioSolutions Inc. (NYSE: EBS) has expanded its distribution capabilities for NARCAN® Nasal Spray by opening a new NARCANDirect™ distribution center in Nevada. This expansion aims to enhance customer delivery experiences across the United States, particularly for West Coast customers. The move is part of Emergent's commitment to broadening access to naloxone nationwide and meeting the increased demand for opioid emergency preparedness.

Key points:

• NARCANDirect™ is an online portal for qualified direct purchasers
• Approximately 64 million doses of NARCAN® Nasal Spray distributed since 2016
• In 2023, Emergent delivered about 11 million cartons (~22 million doses)
• The company is committed to ensuring broad access and strong supply in 2024

Positive

• Expansion of distribution capabilities with a new center in Nevada
• Coast-to-coast distribution mechanisms now in place
• Approximately 64 million doses of NARCAN® Nasal Spray distributed since 2016
• Delivered about 11 million cartons (~22 million doses) in 2023

Negative

• None.

Insights

Supply Chain Analyst

Emergent BioSolutions' expansion of its NARCAN® Nasal Spray distribution capabilities is a strategic move to enhance its supply chain efficiency. The new NARCANDirect™ distribution center in Nevada establishes a coast-to-coast distribution network, potentially reducing delivery times and costs. This expansion aligns with the increasing demand for naloxone, with approximately 64 million doses distributed since 2016 and 22 million doses delivered in 2023 alone.

The improved distribution system could lead to increased market share and customer satisfaction, particularly among public interest customers. However, investors should note that while this expansion may boost sales, it also involves increased operational costs. The long-term impact on profitability will depend on how effectively Emergent can leverage this expanded network to capture market growth in the opioid overdose treatment sector.

Healthcare Policy Analyst

Emergent's expansion of NARCAN® distribution capabilities reflects a proactive response to the ongoing opioid crisis. The company's focus on public interest customers, including emergency services and community-based programs, aligns with national health priorities. This move could potentially strengthen Emergent's position in government contracts and public health initiatives.

However, investors should consider the evolving landscape of opioid response policies. While current demand is high, future changes in healthcare policies or the introduction of alternative treatments could impact NARCAN®'s market position. The company's commitment to "broad access, awareness and strong supply" suggests a long-term strategy to maintain market leadership, but it's important to monitor policy developments that could affect the naloxone market.

• Customer-focused approach and continued investments in NARCAN^® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced the introduction of a new NARCANDirect™ distribution center in Nevada to further demonstrate its commitment to broadening access to NARCAN^® Nasal Spray nationwide. This new facility allows Emergent to further meet the increased demand for naloxone by now having coast-to-coast distribution mechanisms in place to continue to provide faster, more efficient delivery to public interest customers, as well as other purchasing entities.

NARCANDirect™ is an online portal that enables qualified direct purchasers, such as emergency medical services, law enforcement, fire departments, government agencies, schools/universities, and community-based naloxone distribution programs, to purchase and ship NARCAN^® Nasal Spray directly.

“Fighting the opioid epidemic requires a multi-faceted, highly collaborative approach, and the needs of our public interest partners remain a top priority as they work diligently on the frontlines of this epidemic,” said Paul Williams, senior vice president, products head at Emergent. “As part of our continued commitment to respond to the ongoing epidemic, we are introducing this new NARCANDirect™ distribution enhancement that will further ensure our West Coast customers can access NARCAN^® Nasal Spray and can continue to make a positive impact in their communities.”

Since the prescription launch of NARCAN^® Nasal Spray in 2016, approximately 64 million doses have been distributed across the U.S. and Canada. In 2023, Emergent delivered approximately 11 million cartons (~22 million doses), and remains committed to ensuring broad access, awareness and strong supply to meet expected growing demand in 2024 to support distribution efforts across the country.

Visit NARCAN.com for more information.

About NARCAN^® Nasal Spray
NARCAN^® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central nervous system depression.

While NARCAN^® Nasal Spray can be administered by a non-health care professional, it is not intended to be a substitute for professional medical care. Always call 911 as soon as an opioid overdose is suspected, before administering NARCAN^® Nasal Spray. Always read the label and follow the directions for use.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What is the purpose of Emergent BioSolutions' new distribution center for NARCAN® Nasal Spray?

The new NARCANDirect™ distribution center in Nevada aims to enhance customer delivery experiences, particularly for West Coast customers, and meet the increased demand for naloxone across the United States.

How many doses of NARCAN® Nasal Spray has Emergent BioSolutions (EBS) distributed since its launch?

Since the prescription launch of NARCAN® Nasal Spray in 2016, Emergent BioSolutions has distributed approximately 64 million doses across the U.S. and Canada.

What was Emergent BioSolutions' (EBS) distribution volume for NARCAN® Nasal Spray in 2023?

In 2023, Emergent BioSolutions delivered approximately 11 million cartons, which is equivalent to about 22 million doses of NARCAN® Nasal Spray.

Who can purchase NARCAN® Nasal Spray through the NARCANDirect™ portal?

Qualified direct purchasers such as emergency medical services, law enforcement, fire departments, government agencies, schools/universities, and community-based naloxone distribution programs can purchase NARCAN® Nasal Spray through the NARCANDirect™ portal.